focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Share News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Diurnal shares more than double on takeover bid

Tue, 30th Aug 2022 11:04

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

Diurnal Group PLC, shares surge to 26.19 pence from Friday's close of 11.25p, 12-month range 9.5-67.9p. The pharmaceutical company focused on hormonal diseases agrees to be taken over by Neurocrine Biosciences Inc in deal worth GBP48.3 million. Neurocrine is offering 27.5p, cash, for each Diurnal share. Diurnal directors unanimously recommend deal. "We believe that the acquisition is compelling for Diurnal's shareholders given the risks associated with achieving Diurnal's vision of creating a profitable business, in particular the ongoing commercial roll out of Diurnal's products in Europe and the execution of key clinical studies, in addition to the substantial shareholder dilution that is likely to result from accessing the capital required to deliver this vision," says Non-Executive Chair Anders Harfstrand.

----------

SIMEC Atlantis Energy Ltd, up 31% at 2.03p, 12-month range 0.97p-5.3p. The sustainable energy generation firm secures necessary grid variations for the 230 megawatt/460 megawatt hour battery energy storage system at the Uskmouth site and has completed the novation of the grid connection agreement. "With excellent progress being made, the project is on track to be operational by 2024," it says. Adds it now has no loans outstanding with any SIMEC group company.

----------

MyCelx Technologies Corp, up 14% at 48.36p, 12-month range 30.55p-92.00p. The clean water and air technology firm secures new purchase order from SABIC Agri-Nutrients, a SABIC affiliate, to provide clean water for optimal performance in their fertiliser production process. Also wins short-term emergency response project with a independent petrochemical company in Saudi Arabia and secures renewal of two water treatment contracts with long-standing customers in the Middle East. "These projects underpin the 2022 revenue forecast, and the company remains on track to meet current guidance," it says.

----------

AIM - LOSERS

----------

Petroneft Resources PLC, down 28% at 0.645p, 12-month range 0.65p-4.88p. Reports temporary suspension of oil acceptance and transfer from Licence 61 by Nord Imperial LLC. In 2009, contract was signed with Nord Imperial to cover storage and transfer of oil by pipeline from Licence 61 to the Transneft Entry point at Zavyalovo. Petroneft says it has considered contract tariff to be "significantly higher than normal market rates" for some time. Says payments were made to Nord Imperial at reduced levels amid no progress in finding "more equitable" outcome and, in response, Nord Imperial has temporarily suspending the acceptance of oil and transfer. "As the company currently have no other export route from Licence 61, Petroneft is progressively shutting down its wells until the situation can be resolved," it says.

----------

Joules Group PLC, down 7.5% at 23.58p, 12-month range 19.41p-257.00p. Retailer insists it continues in "positive" discussions with Next over a possible investment, despite Sky News over the weekend reporting that talks had stalled. Sky News said it has learnt the two companies are not close to agreeing the terms of an investment from Next, and the FTSE 100-listed retailer had not received enough financial information to allow it to make a formal offer to the Joules board. There were also doubts that Next would want to proceed with a deal at 33p per share or more given Joules shares closed at 25.5p on Friday. The stock has fallen 82% since the start of 2022, and shares had closed at 33p the day before the companies confirmed they were in talks over the potential equity investment.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
11 May 2020 13:07

UK EXECUTIVE CHANGE SUMMARY: Abcam Board Confirms Support For Chair

UK EXECUTIVE CHANGE SUMMARY: Abcam Board Confirms Support For Chair

Read more
15 Apr 2020 14:32

UK TRADING UPDATE SUMMARY: Kromek To Make 2,000 Ventilators For UK

UK TRADING UPDATE SUMMARY: Kromek To Make 2,000 Ventilators For UK

Read more
1 Apr 2020 14:47

Diurnal Gets European Marketing Authorisation For Chronocort

Diurnal Gets European Marketing Authorisation For Chronocort

Read more
6 Mar 2020 17:12

UPDATE: Diurnal Placing Raises GBP11 Million For Drug Development

UPDATE: Diurnal Placing Raises GBP11 Million For Drug Development

Read more
6 Mar 2020 12:40

Diurnal Announces GBP7 Million Placing To Fund Drug Development

Diurnal Announces GBP7 Million Placing To Fund Drug Development

Read more
6 Mar 2020 10:07

Diurnal raises at least ?7m through conditional placing

(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced a conditional placing with institutional investors on Friday, to raise at least ?7m before expenses, at a price of 32p per new share.

Read more
5 Mar 2020 17:21

Diurnal Group Names Director Sam Williams Interim Chair

Diurnal Group Names Director Sam Williams Interim Chair

Read more
13 Feb 2020 13:07

Diurnal Says US FDA Accepts New Drug Application For Alkindi Sprinkle

Diurnal Says US FDA Accepts New Drug Application For Alkindi Sprinkle

Read more
13 Feb 2020 09:47

Diurnal clears FDA hurdle for 'Alkindi Sprinkle'

(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced on Thursday that its new drug application (NDA) for 'Alkindi', or hydrocortisone granules in capsules for opening and to be known in the US as 'Alkindi Sprinkle', has been accepted for review by the US Food and Drug Administration (FDA).

Read more
11 Feb 2020 13:45

Diurnal narrows loss as it progresses drugs to market

(Sharecast News) - Speciality pharmaceutical company Diurnal Group narrowed its first-half loss by 53% to ?4.6m, it announced on Tuesday, which it said reflected improved revenues and a reduction in clinical development expenses for the period.

Read more
11 Feb 2020 09:20

Diurnal Loss Narrows In First Half Amid Improved Sales Of Alkindi

Diurnal Loss Narrows In First Half Amid Improved Sales Of Alkindi

Read more
4 Feb 2020 15:54

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
20 Jan 2020 11:17

Diurnal In Good Health Ahead Of Second Half Amid Alkindi Progress

Diurnal In Good Health Ahead Of Second Half Amid Alkindi Progress

Read more
16 Dec 2019 13:20

Diurnal Submits Market Authorisation Application For Chronocort

Diurnal Submits Market Authorisation Application For Chronocort

Read more
2 Dec 2019 14:40

Diurnal Submits New Drug Application For Aklindi Sprinkle In US

Diurnal Submits New Drug Application For Aklindi Sprinkle In US

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.